Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2262251
Max Phase: Preclinical
Molecular Formula: C26H29ClN2O4S
Molecular Weight: 501.05
Molecule Type: Small molecule
Associated Items:
ID: ALA2262251
Max Phase: Preclinical
Molecular Formula: C26H29ClN2O4S
Molecular Weight: 501.05
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCCC2)C1c1csc(-c2ccc(Cl)cc2)n1
Standard InChI: InChI=1S/C26H29ClN2O4S/c1-4-32-25(30)21-15(2)28-16(3)22(26(31)33-19-8-6-5-7-9-19)23(21)20-14-34-24(29-20)17-10-12-18(27)13-11-17/h10-14,19,23,28H,4-9H2,1-3H3
Standard InChI Key: GWKPERXLJDEEOA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 501.05 | Molecular Weight (Monoisotopic): 500.1537 | AlogP: 6.14 | #Rotatable Bonds: 6 |
Polar Surface Area: 77.52 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 1.96 | CX LogP: 5.45 | CX LogD: 5.45 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.48 | Np Likeness Score: -0.93 |
1. Samzadeh-Kermani A, Shafaroodi H, Miri R, Mirkhani H, Vosooghi M, Shafiee A. (2009) Lipophilic 2-(4-chlorophenyl)-4-thiazolyl-1,4-dihydropyridines: synthesis, calcium channel antagonist activity, and protection against pentylenetetrazole-induced seizure, 18 (2): [10.1007/s00044-008-9112-5] |
Source(1):